We estimate orthopedic sales grew in the mid-single digits for the first quarter of 2022 and that the remaining challenges are manageable.

The company's renewed focus on competitiveness and market share paid off in its fiscal year 2022, as Medtronic grew in the mid-single digits.

The company grew in the high single digits for 1Q22, driven by a company record for procedure volume in March.

The company grew in the high single digits for 1Q22 as its non-elective trauma business offset COVID-related elective procedure headwinds.

The company declined in the double digits for 1Q22 as it continues the early commercialization efforts of its HOLO platform.

The company's orthopedic sales grew 9% organically in 1Q22 as Bioventus targets double-digit organic growth for the full year.

The company grew in the high single-digits during a better than expected 1Q22 and restated its full-year guidance for MACI.